Table 3 Other molecular targeted therapies for ovarian clear cell cancer
Trial name/Clinical. gov. identifier | Phase | Target | Interventions | Patient type | Status |
|---|---|---|---|---|---|
GOG-0268 (NCT01196429) | II | mTOR | Temsirolimus + Carboplatin + Paclitaxel | Stage III-IV OCCC | Completed |
GOD-0254 (NCT00979992) | II | PDGFR VEGFR | Sunitinib | Persistent or recurrent OCCC | Completed |
NRG-GY001 (NCT02315430) | II | MET RET VEGFR2 AXL | Cabozantinib | Persistent or recurrent OCCC | Completed |
ENGOT-GYN1 (NCT02866370) | II | FGFR PDGFR VEGFR | Nintendanib | Persistent or recurrent OCCC and endometrial CCC | On-going |
MEDI-4736 (NCT03405454) | II | PD-L1 | Durvalumab | Persistent or recurrent OCCC | On-going |
BrUOG354 (NCT03355976) | II | PD-L1 CTLA4 | Nivolumab ± Ipilimumab | Persistent or recurrent OCCC or extra-renal origin CCC | On-going |
NRG-GY016 (NCT03602586) | II | PD-1 IDO1 | Pembrolozimab + Epacadostat | Persistent or recurrent OCCC | On-going |
JGOG3022 (NCT04428398) | II | VEGF | Bevacizumab + Carboplatin + Paclitaxel | Stage III-IV epithelial ovarian cancer | Completed |
JAVELIN Solid Tumor Trial (NCT01772004) | II | PD-L1 | Avelumab | Persistent or recurrent OCCC | Completed |